Background. Glioblastoma (GBM) is the most common malignant brain tumor in adults and is nearly always fatal. Emerging evidence suggests that human Cytomegalovirus (HCMV) is present in 90-100% of GBMs and that add-on antiviral treatment for HCMV show promise to improve survival. Methods. In a randomized, placebo-controlled trial of valganciclovir in 42 GBM patients, blood samples were collected for analyses of HCMV DNA, RNA, reactivity against HCMV peptides, IgG, and IgM at baseline and at 3, 12, and 24 weeks of treatment. Results. All 42 tumors were positive for HCMV protein. All patients examined had at least one blood sample positive for HCMV DNA, 63% were HCMV RNA positive, and 21% were IgM positive. However, 29% of GBM patients were IgG negative for HCMV. Five of these samples were positive in an enzyme-linked immunosorbent assay (ELISA) that used antigens derived from a clinical isolate. Blood T cells from 11 of 13 (85%) HCMV IgG-negative GBM patients reacted against HCMV peptides. Valganciclovir did not affect IgG titers, DNA, or RNA levels of the HCMV immediate early (HCMV IE) gene in blood. Conclusion. In GBM patients, HCMV activity is higher than in healthy controls and serology is a poor test to define previous or active HCMV infection in these patients.
Keywords: ELISA, enzyme-linked immunosorbent assay; FACS, flow cytometry analyses; FITC, fluorescein isothiocyanate; GBM, glioblastoma; HCMV IE, human Cytomegalovirus-immediate early; HCMV, human Cytomegalovirus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; PBMC, Peripheral blood mononuclear cells; PBS, Phosphate buffered saline; PCR, polymerase chain reaction; SEB, staphylococcal snterotoxin B; VIGAS study, Efficacy and Safety of Valcyte® as an Add-on Therapy in Patients with Malignant Glioblastoma and cytomegalovirus infection; Valcyte; cytomegalovirus; glioblastoma; peptides stimulation; serology; valganciclovir.